Brooks Laboratories Ltd
₹65.54
(6.54%)
Tue, 13 Oct 2026, 11:41 pm
Health Technology
Pharmaceuticals: Major
24.5KBrooks Laboratories Ratios
| Particulars | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 0 | 2.99 | 3.68 | 4.12 | 6.54 | 13.08 | 131.41 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price to book ratio | 0 | 0 | 0 | 0 | 0 | 0.29 | 0.25 | 0.27 | 0.56 | 1.14 | 1.71 | 1.13 | 0.82 | 0.38 | 1.94 | 2.05 | 2.09 | 3.71 | 3.24 |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | 0.47 | 0.33 | 0.35 | 0.73 | 1.74 | 3.81 | 2.32 | 1.61 | 0.39 | 1.99 | 1.98 | 2.46 | 3 | 3.51 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 0 | 0 | 4.95 | 2.55 | 15.44 | 16.15 | 25.28 | 0 | 0 | 0 | 95.02 | 0 | 0 | 0 | 154.52 |
| Enterprise value | 0 | 0 | 0 | 0 | 0 | 7.78Cr | 3.52Cr | -670780 | 39.5Cr | 143Cr | 231Cr | 156Cr | 116Cr | 53.05Cr | 183Cr | 248Cr | 160Cr | 243Cr | 295Cr |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | 0 | 0.73 | 0.34 | -0.01 | 5.76 | 12.59 | 45.81 | 0 | 0 | 0 | 0 | 0 | 0 | 81.65 | 61.96 |
| Debt to equity ratio | 4.58 | 2.31 | 1.92 | 0.87 | 0.45 | 0.01 | 0.01 | 0 | 0 | 0.05 | 0.11 | 0.24 | 0.30 | 0.28 | 0.40 | 0.29 | 0.09 | 0.09 | 0.08 |
| Return on equity % | 0 | 100.89 | 43.16 | 47.32 | 41.82 | 15.97 | 7.26 | 6.65 | 8.46 | 9.11 | 1.33 | -11.38 | -13.48 | -23.95 | -21.82 | -13.55 | -25.88 | -28.08 | -12.18 |
Brooks Laboratories Ltd Ratios
The Brooks Laboratories Ltd Ratios page provides a complete fundamental analysis of Brooks Laboratories Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Brooks Laboratories Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Brooks Laboratories Ltd (NSE: BROOKS, BSE: 533543) is currently trading at ₹65.54, with a market capitalization of ₹206.5Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Brooks Laboratories Ltd remains a key stock for fundamental analysis using Brooks Laboratories Ltd Ratios.
Brooks Laboratories Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Brooks Laboratories Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Brooks Laboratories Ltd Ratios.
Historically, the Brooks Laboratories Ltd P/E ratio has shown strong fluctuations:
- 2024: 0
- 2023: 0
- 2022: 0
- 2021: 0
- 2020: 0
The decline in Brooks Laboratories Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Brooks Laboratories Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 3.24.
Historical P/B trend:
- 2024: 3.24
- 2023: 3.71
- 2022: 2.09
- 2021: 2.05
Brooks Laboratories Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Brooks Laboratories Ltd P/S ratio currently stands at 3.51, an important part of Brooks Laboratories Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 3.51
- 2023: 3
- 2022: 2.46
- 2021: 1.98
The rising Brooks Laboratories Ltd P/S ratio indicates improved revenue valuation by investors.
Brooks Laboratories Ltd Price to Cash Flow Ratio (P/CF)
The Brooks Laboratories Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 154.52.
Historical Brooks Laboratories Ltd Price to Cash Flow Ratio:
- 2024: 154.52
- 2023: 0
- 2022: 0
- 2021: 0
- 2020: 95.02
The rising Brooks Laboratories Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.
Brooks Laboratories Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Brooks Laboratories Ltd EV currently stands at ₹295Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 295Cr
- 2023: 243Cr
- 2022: 160Cr
- 2021: 248Cr
Brooks Laboratories Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Brooks Laboratories Ltd EV/EBITDA ratio is currently 61.96, a key metric in Brooks Laboratories Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 61.96
- 2023: 81.65
- 2022: 0
- 2021: 0
Stable Brooks Laboratories Ltd EV/EBITDA indicates balanced valuation.
Brooks Laboratories Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Brooks Laboratories Ltd D/E ratio is currently 0.08, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.08
- 2023: 0.09
- 2022: 0.09
- 2021: 0.29
Brooks Laboratories Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Brooks Laboratories Ltd ROE currently stands at -12.18%, showing profitability and capital efficiency.
Historical ROE:
- 2024: -12.18
- 2023: -28.08
- 2022: -25.88
- 2021: -13.55
Declining ROE indicates pressure on profitability.
Brooks Laboratories Ltd Ratios Analysis Summary
The Brooks Laboratories Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Brooks Laboratories Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Brooks Laboratories Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
